Unproven Autism Cure Pushed From Podium

A single White House briefing helped push an unapproved autism therapy into clinics before the science was settled.

At a Glance

Prescribing of leucovorin for autism rose nationwide after a 2025 White House briefing.
Small trials show signals in language and social scores, often in select subgroups.
Pediatrics leaders say evidence is too limited for routine use in autistic children.
The largest positive trial was retracted, raising fresh questions about reliability.

What changed after the White House spotlight

Brown University researchers tracked prescribing patterns after a September 2025 White House briefing that promoted leucovorin as a possible autism treatment. They found sharp shifts in how doctors ordered both acetaminophen and leucovorin across the country. That timing tied the podium to practice in real life, not just talk on cable news. Policy theater met clinic workflow, and it moved fast enough to outpace medical consensus.

Speed can help when a therapy is well supported. This one is not there yet. Leucovorin, a reduced form of folate used in cancer care, has early autism studies that are small, mixed, and often focused on narrow outcomes. The strongest signals cluster in children with folate receptor alpha autoantibodies, a plausible biological subgroup. That pattern hints at promise, but it does not equal broad proof. Leaders in pediatrics warn against racing ahead of the data.

What the clinical studies actually show

A 2016 double-blind randomized trial reported greater gains in verbal communication with high-dose folinic acid versus placebo, with a medium-to-large effect size. The benefit looked stronger in children who tested positive for folate receptor alpha autoantibodies. That created a clear, testable story: match a biomarker to a targeted treatment and you might help language in a subset of autistic children.

A separate randomized trial, called EFFET, reported improvement at 12 weeks on global and social-communication scores on a standard autism scale. The dose was lower than in the 2016 study, and the trial was single-center and short. The result kept interest alive but did not settle the debate. Such findings say “maybe, in some kids, for certain measures,” not “go write every child a script”.

The pushback from pediatric leaders

The American Academy of Pediatrics states it does not recommend routine leucovorin use for autistic children. The group cites small samples, method limits, and a lack of large, independent, multi-center trials. That stance does not bury the idea of leucovorin. It asks for better evidence first. That is the right order in a field where families carry most of the risk and cost if hype outruns proof.

The caution grew after a major setback. The largest published randomized trial of leucovorin for autism traits was retracted due to data issues. Retractions like this are uncommon and serious. They do not erase all prior signals, but they do reset trust. When the biggest brick in the wall gets pulled, builders should slow down and inspect the rest before adding new floors.

How to square hope, evidence, and common sense

Parents want tools that help now. Clinicians want options beyond waitlists and generic advice. Policymakers want to be seen backing solutions. Those motives can align with American conservative values when they favor prudent steps, local control, and real results. The clean path here looks like this: test for folate receptor alpha autoantibodies when clinically appropriate, enroll eligible kids in rigorous trials, and avoid routine off-label use until larger, independent studies confirm safety and benefit.

Families deserve clarity, not mixed signals from podiums and preprints. The next milestones are straightforward. Finish multi-center, double-blind randomized trials with clear language and social endpoints. Pre-register outcomes. Share data for independent checks. If benefits hold, update guidelines fast. If they do not, say so and move on. Science is not anti-hope; it is how we keep hope honest enough to help.